Literature DB >> 22698736

[The different epidemic and evolution of HCV genotypes].

Lu Zhao1, Yue Feng, Xue-Shan Xia.   

Abstract

Hepatitis C virus (HCV) is a prevalent and globally distributed human pathogen that currently infects an estimated 170 million people. Chronic HCV infection significantly increases the risk of chronic hepatitis. The virus exhibits a very high degree of genetic diversity that is classified six genotypes and sub-classified more than 80 subtypes by phylogenetic analysis. The various genotypes and subtypes of HCV have been associated with different epidemiological and geographical spread patterns. Genotypes 1 and 2 are globally distributed; genotype 3 is predominant in Asia, North America and parts of Europe; similar regional patterns of endemic diversity have been found for genotype 4 in Europe, Middle East and Central Africa, for genotype 5 in parts of Africa and Europe, and for genotype 6 in Southeast Asia and North America. Up to date, four HCV genotypes, including genotype 1, 2, 3 and 6, were identified in China. Genotypes 1b and 2a were mainly found in Northern China. The fast spreading of genotypes 3 and 6 in Southern and South-Western China was reported by recent studies. It's deduced that Yunnan may become an important source of HCV epidemic and spread, which will cause great changes in the distribution of HCV genotypes and subtypes, and a variety of transmission. With the development of evolution theory and related analysis methods, such as coalescent theory and evolutionary molecular, it is possible to understand the characters of virus evolution and migration. For HCV, the further understanding on the prevalence and evolution characters of various genotypes is very important for the deep investigation of HCV epidemic and the development of prevention strategy.

Entities:  

Mesh:

Year:  2012        PMID: 22698736     DOI: 10.3724/sp.j.1005.2012.00666

Source DB:  PubMed          Journal:  Yi Chuan        ISSN: 0253-9772


  7 in total

1.  Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR.

Authors:  Marzieh Jamalidoust; Mandana Namayandeh; Sadaf Asaei; Nasrin Aliabadi; Mazyar Ziyaeyan
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  Comparison of Elecsys Anti-HCV II Assay With Other HCV Screening Assays.

Authors:  Dongdong Li; Siyuan Zhu; Tingting Wang; Jingna An; Lanlan Wang; Chuanmin Tao
Journal:  J Clin Lab Anal       Date:  2015-12-14       Impact factor: 2.352

Review 3.  Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia.

Authors:  Shaodong Ye; Lin Pang; Xiaochun Wang; Zhongfu Liu
Journal:  Curr HIV/AIDS Rep       Date:  2014-06       Impact factor: 5.071

4.  Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

Authors:  Reham Abdel-Wahab; Samir Shehata; Manal M Hassan; Lianchun Xiao; Ju-Seog Lee; Sheree Cheung; Hoda H Essa; Hesham M Hassabo; Ahmed S Shalaby; Eman Mosad; Kanwal Raghav; Asif Rashid; Robert A Wolff; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncotarget       Date:  2015-08-28

Review 5.  Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection.

Authors:  Seyed Hamid Moosavy; Parivash Davoodian; Mirza Ali Nazarnezhad; Abdolazim Nejatizaheh; Ebrahim Eftekhar; Hamidreza Mahboobi
Journal:  Electron Physician       Date:  2017-10-25

6.  Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.

Authors:  Shaobo Zhang; Xiaoxi Ouyang; Xin Jiang; Dayong Gu; Yulong Lin; S K Kong; Weidong Xie
Journal:  Int J Med Sci       Date:  2015-07-16       Impact factor: 3.738

7.  Molecular epidemiologic characterization of a clustering HCV infection caused by inappropriate medical care in Heyuan City of Guangdong, China.

Authors:  Yi-Qun Kuang; Jin Yan; Yan Li; Xuhe Huang; Ye Wang; Guolong Yu; Xinge Yan; Ping Lin; Bing Qin; Peng Lin
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.